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The ryanodine receptor / Ca2+ release channel (RyR2) is one of the main
actors of the excitation-contraction coupling in the heart. Single-point muta-
tions on RyR2 have been associated with catecholaminergic polymorphic ven-
tricular tachycardia (CPVT) and arrhythmogenic right ventricular dysplasia
(ARVD) and sudden cardiac death.
In this study, we characterized a novel heterozygous RyR2 mutation found
in a 31-year-old female and her mother with syncope at rest and recurrent
short-coupled premature ventricular contractions (PVCs) initiating polymor-
phic ventricular tachycardia (PMVT). Using site-directed mutagenesis, we
expressed human RyR2-H29D mutant channels with its stabilizing protein
calstabin2 (FKBP12.6). Single channel measurements of RyR2-H29D chan-
nels revealed significantly higher open probability (Po) and opening frequency
(Fo) at diastolic levels of cytosolic Ca2+ when compared with RyR2-WT
channels under non-stress conditions (i.e. in absence of PKA phosphoryla-
tion). This leaky phenotype at rest in RyR2-H29D channels was associated
with a modest but significant depletion of calstabin2 binding from the RyR2
macromolecular complex when compared to RyR2-WT channels. Interes-
tingly, under stress conditions, RyR2-H29D channels also exhibited a signifi-
cant higher Po and Fo at diastolic concentrations of Ca2+ while no significant
depletion of calstabin2 was observed.
In conclusion, the RyR2-H29D mutation is associated with a clinical phe-
notype of short-coupled PMVT at rest. In contrast to CPVT-associated RyR2
mutations, RyR2-H29D causes a leaky channel at diastolic levels of Ca2+
under non-stress conditions. Leaky RyR2 may be an under-recognized
mechanism for idiopathic PMVT at rest.
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Introduction: Several gene defects are associated with idiopathic ventri-
cular fibrillation (IVF) and sudden cardiac death (SCD). The recent develop-
ment of NGS-based mutation screening provides a unique opportunity to
estimate extensively the spectrum and prevalence of rare variants in genes
associated with cardiac diseases.
Methods: Cohort 1 was composed of 75 patients resuscitated from cardiac
arrest due to IVF. All patients have undergone a complete clinical cardiac
examination including 12 lead-ECG, cardiac echography, coronography and
exercise test.
Cohort 2 was composed of 99 victims of SCD related to ventricular fibril-
lation younger than 45 years old and without explanation for the SCD at the
time of the reanimation.
Genetic screening was based on the use of the HaloPlex™ Target Enrich-
ment System (Agilent Technologies) prior to HiSeq sequencing (Illumina).
The custom kit designed for this study covers 163 genes previously reported
as involved in cardiac arrhythmias, conduction defect and cardiomyopathies.
Results: In cohort 1, the mean age was 36±10 years with a male predo-
minance (52 males, 69%). In cohort 2, the mean age was 37±7 years with a
male predominance (76 males, 79%).
In cohort 1, we identified 50 putative mutations in 35 patients (47%). In
cohort 2, we identified 30 putative mutations in 24 patients (24%).
Conclusion: Our study identified mutations in almost 50 % of IVF patients
after a complete cardiac evaluation. These results suggest that molecular ana-
lysis must be part of the work up in this kind of patients. In young patients
affected by unexplained sudden death, the molecular analyses are less contri-
butive probably because of a more important percentage of patients affected
by ischemic cardiomyopathies.
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Introduction: Inactivating mutations in the SCN5A and frequent variants
in SCN10A, SCN5A and HEY2 genes have been both associated with Brugada
syndrome. The myocardial transmural electrical gradient that could explain
the ‘Brugada’ ECG pattern, is considered as increased by inactivation of the
sodium channel. Na channel blocker drug can likewise increase or unmask this
pattern. To better assess phenotype correlation with those SCN5A mutation
and frequent variants, we compare ECG parameters during Na channel blocker
test according to the genetical status.
Methods: ECG parameters (P, PR, QRS, QT peak and QT end intervals; J
wave amplitude in V1, V2, V3) were double measured in 73 unrelated Bru-
gada patients with a positive Na blocker challenge. Data were measured at
baseline and at the end of the test. Each patient was screened for SCN5A muta-
tion and SCN10A, SCN5A and HEY2 frequent variants by direct sequencing
and genotyped using Axiom Genome-Wide CEU 1 arrays (Affymetrix).
Results: The 10 patients carrying known SCN5A mutations (14%) didn’t
show any clinical differences at baseline with those without SCN5A mutation.
Baseline ECGs revealed a lengthening of PR (181 ±27 vs 156 ±30 ; p=0.017)
and QRS interval (101 ±15 vs 89 ±14 ; p=0.020). No other parameter was sig-
nificantly different. Once ECG parameters fulfilled diagnostic criteria for Bru-
gada pattern, ECG parameters were not significantly different in the 2 groups.
A similar effect on ECG was found in patients without SCN5A mutations but
carrying more than 4 frequent variants. SCN10A polymorphism (rs10428132)
was associated with a progressive effect on PR (p=0.044) and QRS (p=0.030)
duration according to the risk allele number. According to the genetic status,
no clinical difference was found after a mean follow up of 6 years.
Abstract 0185-Table
Cohort 1 (n=75) Cohort 2 (n=99) 
SCN5A 7 (9%) 0
HCM and DCM genes 22 (29%) 17 (17%)
ARVD/C genes 4 (5%) 3 (3%)
LQTS genes (excluding SCN5A) 4 (5%) 4 (4%)
CPVT genes (excluding SCN5A) 7 (9%) 3 (3%)
BRS genes 3 (4%) 1 (1%)
Other 3 (4%) 2 (2%)
